Sparta Biomedical is a developer of orthopedic solutions. The company’s SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the FDA. SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee. Sparta’s mission is to empower orthopedic surgeons with advancements that fundamentally restore movement for their patients.
Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant
Success Story
Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant
DURHAM, N.C., March 17, 2021 /PRNewswire/ — Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee.